Previous studies reported the abundance of also CD163+ anti‐inflammatory/pro‐fibrotic macrophages in late‐stage COVID‐19.[25] While we observed a robust accumulation of pro‐inflammatory macrophages in COVID‐E samples, discrepancies across studies may result from several factors, including differences in tissue procurement protocols, donor heterogeneity (e.g., disease severity and treatment history), and variations in analytical pipelines. Here, CD163 is linked to COVID-19.